Functional Characterization of Nonsynonymous Single Nucleotide Polymorphisms in the Human Organic Anion Transporter 4 (hOAT4)

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2009 Dec 18

PMID 20015291

Citations 17

Authors

Fanfan Zhou

Ling Zhu

Pei H Cui

W Bret Church

Michael Murray

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: The human organic anion transporter (hOAT) family of transmembrane carrier proteins mediate the cellular flux of anionic substances, including certain hormones and anti-cancer drugs. hOAT4 is highly expressed at the apical membrane of the renal tubular cell and facilitates drug re-absorption in the kidney. In the present study, the impact of 10 nonsynonymous single nucleotide polymorphisms (SNPs) of hOAT4 on transport function in COS-7 cells was characterized.

Experimental Approach: Transport uptake assay was used to assess the function of the variant transporters. Cell surface biotinylation and western blot analysis were used to investigate the expression characteristics of the transporter proteins. Comparative modelling was used to interpret the influence of nonsynonymous changes in terms of hOAT4 structure.

Key Results: Four naturally occurring hOAT4 variants (L29P, R48Y, V155G and T392I) exhibited a significant loss of function. Substitution of leucine-29, which is a conserved residue in OATs, with a proline residue, impaired the synthesis or the apparent stability of the transporter and membrane insertion was disrupted in the R48Y variant. In the case of the V155G and T392I variants, impaired function was due to decreased affinity of the transporter for oestrone sulphate and impaired transporter-substrate turnover respectively. The T392I variant was inhibited more extensively than the wild-type transporter by the cationic substrate tetraethyl ammonium.

Conclusions And Implications: Several naturally occurring SNPs encode variant hOAT4s that may impair the renal tubular re-absorption of important drug substrates.

Citing Articles

Examining the Association of Rare Allelic Variants in Urate Transporters , , and with Hyperuricemia and Gout.

Vavra J, Pavelcova K, Masinova J, Hasikova L, Bubenikova E, Urbanova A Dis Markers. 2024; 2024:5930566.

PMID: 38222853 PMC: 10787658. DOI: 10.1155/2024/5930566.

Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia.

Sun H, Wu Y, Bian H, Yang H, Wang H, Meng X Front Pharmacol. 2021; 12:667753.

PMID: 34335246 PMC: 8317579. DOI: 10.3389/fphar.2021.667753.

Structural Insights into the Atomistic Mechanisms of Uric Acid Recognition and Translocation of Human Urate Anion Transporter 1.

Zhao Z, Jiang Y, Li L, Chen Y, Li Y, Lan Q ACS Omega. 2021; 5(51):33421-33432.

PMID: 33403304 PMC: 7774290. DOI: 10.1021/acsomega.0c05360.

The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients.

Kim H, Veal G, Zhou F, Boddy A Eur J Clin Pharmacol. 2018; 74(12):1575-1584.

PMID: 30167756 DOI: 10.1007/s00228-018-2544-z.

Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.

Lozano E, Briz O, Macias R, Serrano M, Marin J, Herraez E J Pers Med. 2018; 8(2).

PMID: 29659532 PMC: 6023491. DOI: 10.3390/jpm8020014.

References

You G . Structure, function, and regulation of renal organic anion transporters. Med Res Rev. 2002; 22(6):602-16. DOI: 10.1002/med.10019. View

Santner S, Leszczynski D, Wright C, Manni A, Feil P, Santen R . Estrone sulfate: a potential source of estradiol in human breast cancer tissues. Breast Cancer Res Treat. 1986; 7(1):35-44. DOI: 10.1007/BF01886734. View

Davis I, Leaver-Fay A, Chen V, Block J, Kapral G, Wang X . MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007; 35(Web Server issue):W375-83. PMC: 1933162. DOI: 10.1093/nar/gkm216. View

Ugele B, St-Pierre M, Pihusch M, Bahn A, Hantschmann P . Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab. 2002; 284(2):E390-8. DOI: 10.1152/ajpendo.00257.2002. View

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

Lee W, Kwak J, Hwang J, Suh C, Cha S . Identification and characterization of single nucleotide polymorphisms of SLC22A11 (hOAT4) in Korean women osteoporosis patients. Mol Cells. 2008; 25(2):265-71. View

Santner S, Feil P, Santen R . Biological significance of aromatase activity in human breast tumors. J Clin Endocrinol Metab. 1983; 57(6):1125-8. DOI: 10.1210/jcem-57-6-1125. View

Zhou F, Tanaka K, Pan Z, Ma J, You G . The role of glycine residues in the function of human organic anion transporter 4. Mol Pharmacol. 2004; 65(5):1141-7. DOI: 10.1124/mol.65.5.1141. View

Hong M, Zhou F, You G . Critical amino acid residues in transmembrane domain 1 of the human organic anion transporter hOAT1. J Biol Chem. 2004; 279(30):31478-82. DOI: 10.1074/jbc.M404686200. View

10.

Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M . Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci. 2004; 94(3):297-304. DOI: 10.1254/jphs.94.297. View

11.

Feng B, Shu Y, Giacomini K . Role of aromatic transmembrane residues of the organic anion transporter, rOAT3, in substrate recognition. Biochemistry. 2002; 41(28):8941-7. DOI: 10.1021/bi0200615. View

12.

Zhou F, Pan Z, Ma J, You G . Mutational analysis of histidine residues in human organic anion transporter 4 (hOAT4). Biochem J. 2004; 384(Pt 1):87-92. PMC: 1134091. DOI: 10.1042/BJ20040751. View

13.

Hocherl K, Schmidt C, Bucher M . COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex. Kidney Int. 2008; 75(4):373-80. DOI: 10.1038/ki.2008.557. View

14.

Tanaka K, Xu W, Zhou F, You G . Role of glycosylation in the organic anion transporter OAT1. J Biol Chem. 2004; 279(15):14961-6. DOI: 10.1074/jbc.M400197200. View

15.

Thompson J, Higgins D, Gibson T . CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994; 22(22):4673-80. PMC: 308517. DOI: 10.1093/nar/22.22.4673. View

16.

Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T . Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003; 73(6):554-65. DOI: 10.1016/S0009-9236(03)00060-2. View

17.

Xu G, Bhatnagar V, Wen G, Hamilton B, Eraly S, Nigam S . Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int. 2005; 68(4):1491-9. DOI: 10.1111/j.1523-1755.2005.00612.x. View

18.

Srimaroeng C, Perry J, Pritchard J . Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica. 2008; 38(7-8):889-935. PMC: 2644066. DOI: 10.1080/00498250801927435. View

19.

LARKIN M, Blackshields G, Brown N, Chenna R, McGettigan P, McWilliam H . Clustal W and Clustal X version 2.0. Bioinformatics. 2007; 23(21):2947-8. DOI: 10.1093/bioinformatics/btm404. View

20.

Erdman A, Mangravite L, Urban T, Lagpacan L, Castro R, De La Cruz M . The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol. 2005; 290(4):F905-12. DOI: 10.1152/ajprenal.00272.2005. View